LLE improved CRS-induced anxiety- and depression-like behaviors, reduced microglial activation in the hippocampus, and suppressed TLR4/MyD88/NF-κB signaling and downstream cytokine release (TNF-α, IL-6, IL-1β). Here, IL1B is linked to depressive disorder.